 SUZHOU, China and SAN FRANCISCO, July 19, 2021 GLOBE NEWSWIRE -- Eluminex Biosciences Suzhou Limited Eluminex, an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, announced today that it has exclusively licensed global rights for the development and commercialization of an investigational biosynthetic cornea derived from recombinant human collagen Type III intended to treat patients with corneal blindness, from FibroGen, Inc. FibroGen; NASDAQ: FGEN. 